Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1029 add-on crossover study in adults with persistent asthma uncontrolled on montelukast
2012-000642-35Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MK-1029 in persistent asthma and allergic asthma (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in FEV1 at end of 4-week treatment period. Started Jul 2012; status: completed.
02
Drugs
MK-1029
03
Conditions
persistent asthmaallergic asthma
Beyond the preview
Go deeper on 2012-000642-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000642-35.